Expert Directory
Neeraj Agarwal, MD, FASCO
Medical Oncologist and Faculty
Dana-Farber Cancer Institute
Codirector
Dana-Farber/Harvard Cancer Consortium Prostate Cancer Program
Boston, MA
Neeraj Agarwal, MD, FASCO, is a medical oncologist and faculty member at Dana-Farber Cancer Institute. He is also codirector of the Dana-Farber/Harvard Cancer Consortium Prostate Cancer Program in Boston, MA.
After receiving his medical training at All India Institute of Medical Sciences in New Delhi, Dr Agarwal completed an internal medicine residency and a geriatric medicine fellowship at The University of Iowa, followed by a hematology-oncology fellowship at HCI.
Dr Agarwal is an internationally recognized physician-scientist in the field of genitourinary cancers. He is the overall study chair of multiple phase 1/2 and phase 3 trials, and he is a steering committee member of numerous other trials. He has received the SWOG Young Investigator Award, the William D. Odell Young Investigator Award, and the National Cancer Institute Cancer Clinical Investigator Team Leadership Award.
He has authored more than 500 peer-reviewed articles and book chapters. He is a panel member for the National Comprehensive Cancer Network and the American Society of Clinical Oncology (ASCO) guideline committees for genitourinary cancers and an advisor to the Oncologic Drugs Advisory Committee and the US Food and Drug Administration. Dr Agarwal holds numerous scientific communications leadership roles, including editor in chief of the ASCO Daily News and editorial board member of several journals. He also serves as a member of the ASCO Genitourinary Cancers Advisory Panel and was named a fellow of ASCO.
Contributing Articles
Balancing Precision in Patient Selection With Equitable Access to Therapy
PARP Inhibitor Benefit in Patients With Metastatic Castration-Resistant Prostate Cancer
The Evolving Role of Prostate-Specific Membrane Antigen Positron Emission Tomography Across the Prostate Cancer Disease Continuum
Current Approaches to Metastatic Hormone-Sensitive Prostate Cancer